Combined results from two studies of an experimental Alzheimer’s drug suggest it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies on the drug — Eli Lilly & Co.’s solanezumab — missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living. But pooled [...]
Posts Tagged ‘mild cases of Alzheimer’s disease’
Alzheimer’s Drug Shows Positive Results In Mild Cases
October 10th, 2012 
admin 
Posted in Articles, Resources 
Tags: alzheimer's disease, Alzheimer's drug, Alzheimer's patients, Alzheimer's Research, alzheimer's treatment, Dementia, early-stage Alzheimer's disease, Eli Lilly, Eli Lilly & Co., Food and Drug Administration, Gammagard, Lilly Bio-Medicines, mental decline in mild Alzheimer's patients, mild Alzheimer's patients, mild cases of Alzheimer's disease, mild to moderate Alzheimer's, National Institute on Aging, patient with Alzheimer's disease, patients with mild disease, person with Alzheimer's, solanezumab 
1 Comment »
Studies: Alzheimer’s Drug May Stabilize Brain Plaque
September 12th, 2012 admin An experimental drug that failed to stop mental decline in Alzheimer’s patients also signaled potential benefit that suggests it might help if given earlier, fuller results of two major studies show. Some patients on the drug had stable levels of brain plaque and less evidence of nerve damage compared to others who were given a dummy treatment, researchers reported [...]
Posted in Articles, Resources Tags: alzheimer's disease, Alzheimer's drug, Alzheimer's Drug May Stabilize Brain Plaque, alzheimer's treatment, bapineuzumab, brain imaging, brain plaque, develop Alzheimer's disease, early-stage Alzheimer's disease, mental decline in Alzheimer's patients, mild cases of Alzheimer's disease, mild mental impairment, mild to moderate Alzheimer's, patient with Alzheimer's disease, people with mild cognitive impairment, person with Alzheimer's, solanezumab, symptom of Alzheimer's, symptoms of dementia No Comments »
Alzheimer’s Drug Fails Study But Flashes Potential
August 26th, 2012 admin An Alzheimer’s treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases of the mind-robbing condition that is notoriously difficult to treat. The Indianapolis drugmaker’s announcement could be a step toward a long-awaited breakthrough in the fight [...]
Posted in Articles, Resources Tags: alzheimer's disease, alzheimer's treatment, Dementia, early-stage Alzheimer's disease, Eli Lilly, Eli Lilly and Co, Food and Drug Administration, Lilly Bio-Medicines, Mayo Clinic's Alzheimer's Disease Research Center, mild cases of Alzheimer's disease, mild to moderate Alzheimer's, Mount Sinai School of Medicine, patient with Alzheimer's disease, person with Alzheimer's, search for a better Alzheimer's treatment, slow memory decline, solanezumab, solanezumab slowed the progression of Alzheimer's No Comments »
